Michael Gelband’s Larimar Therapeutics LRMR Stock Holding History

Michael Gelband’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$276K	Buy	90,413 +63,968	+242%	+$254K	﹤0.01%	1376
2026 Q1	$119K	Sell	26,445 -317,801	-92%	-$1.27M	﹤0.01%	1427
2025 Q4	$1.31M	Buy	344,246 +181,425	+111%	+$706K	0.01%	896
2025 Q3	$526K	Buy	+162,821	New	+$611K	0.01%	1168
2024 Q4	–	Sell	-21,119	Closed	-$138K	–	1812
2024 Q3	$138K	Buy	+21,119	New	+$170K	﹤0.01%	1492
2021 Q2	–	Sell	-36,632	Closed	-$535K	–	2610
2021 Q1	$535K	Sell	36,632 -22,774	-38%	-$414K	0.01%	1296
2020 Q4	$1.27M	Buy	+59,406	New	+$1.19M	0.01%	734

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Michael Gelband's LRMR Position: Q2 2026 in Review

Michael Gelband increased its Larimar Therapeutics (LRMR) stake by 242% in Q2 2026, buying an estimated $254K and bringing the position to 90,413 shares worth $276K. The position accounts for ﹤0.01% of the portfolio, ranked #1376.

Michael Gelband first reported a position in LRMR in Q4 2020 and has held it in 7 quarters since. The position peaked at $1.31M in Q4 2025. 161 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

Michael Gelband held 90,413 shares of Larimar Therapeutics worth $276K as of Q2 2026.
Michael Gelband bought 63,968 Larimar Therapeutics shares in Q2 2026, an estimated $254K.
Larimar Therapeutics made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1376 holding.
Michael Gelband first reported a position in Larimar Therapeutics in Q4 2020 and has held it in 7 quarters since.
Michael Gelband's Larimar Therapeutics position peaked at $1.31M in Q4 2025.
161 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.